Sanofi (EPA:SAN)
France
· Delayed Price · Currency is EUR | Market Cap | 90.10B |
| Revenue (ttm) | 47.35B |
| Net Income (ttm) | 7.56B |
| Shares Out | 1.20B |
| EPS (ttm) | 6.20 |
| PE Ratio | 18.94 |
| Forward PE | 8.69 |
| Dividend | 4.12 (5.49%) |
| Ex-Dividend Date | May 5, 2026 |
| Volume | n/a |
| Average Volume | 2,827,032 |
| Open | 74.27 |
| Previous Close | 73.76 |
| Day's Range | 73.47 - 75.07 |
| 52-Week Range | 71.25 - 91.15 |
| Beta | 0.28 |
| RSI | 49.67 |
| Earnings Date | Jul 30, 2026 |
About Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for onc... [Read more]
Financial Performance
In 2025, Sanofi's revenue was 46.72 billion, an increase of 5.49% compared to the previous year's 44.29 billion. Earnings were 7.81 billion, an increase of 40.52%.
Financial StatementsAnalyst Forecast
According to 24 analysts, the average rating for SAN stock is "Buy." The 12-month stock price target is €96.70, which is an increase of 28.81% from the latest price.
News
Healthcare stocks have become a haven for investors ditching tech
Shares of AbbVie, Eli Lilly and Johnson & Johnson were on track to hit all-time highs Friday, in the latest signal that investor appetite for the biopharmaceutical sector is back.
Sanofi Faces EU Probe With Fines Possibly Reaching 10%
Sanofi Faces EU Probe With Fines Possibly Reaching 10%
Sanofi (SNY) Faces EU Antitrust Investigation Over Vaccine Marketing Practices
Sanofi (SNY) Faces EU Antitrust Investigation Over Vaccine Marketing Practices
EU Commission opens antitrust probe into Sanofi's flu vaccine campaign
The European Commission opened on Friday an investigation into whether French drug giant Sanofi breached EU competition rules in a flu vaccine marketing campaign.
Is Kymera Therapeutics The Next Big Rival To Regeneron And Sanofi?
Kymera Therapeutics shares catapulted Thursday after the company wrapped enrollment in an eczema study six months ahead of expectations.
Press Release: Sanofi Foundation opens new chapter centered on future generations
Sanofi Foundation opens new chapter centered on future generations Paris, June 2 5 , 2026 . The Sanofi Foundation is opening a new chapter with a strengthened commitment to children and young people, ...
MacroGenics To Receive $24.5 Mln Milestone Payment From Sanofi For Recent TZIELD Approval
(RTTNews) - MacroGenics, Inc. (MGNX), a clinical-stage biopharmaceutical company, announced that it will receive a $24.5 million regulatory milestone payment from Sanofi following the recently granted...
Sanofi Wins EU Approval For Cenrifki As First Disability-Targeting Therapy For SPMS Without Relapses
(RTTNews) - Sanofi (SNY) announced that the European Commission has approved Cenrifki (tolebrutinib) as the first medicine in the European Union specifically designed to slow disability progression in...
Sanofi Receives Marketing Rights For Wayrilz In Immune Thrombocytopenia From Japan's MHLW
(RTTNews) - Sanofi (SNY) announced that the Ministry of Health, Labour, and Welfare (MHLW) in Japan has granted marketing and manufacturing approval for Wayrilz in the treatment of persistent or chron...
EU Approves Sanofi's Cenrifki For Non-Relapsing Secondary Progressive Multiple Sclerosis
PARIS (dpa-AFX) - Sanofi SA (SNY) on Tuesday said the European Commission has approved Cenrifki for the treatment of secondary progressive multiple sclerosis (SPMS) in adults who have not experien...
Sanofi Multiple Sclerosis Drug Gets EU Approval
The authorization of Cenrifki for the treatment of secondary progressive multiple sclerosis without relapses follows a rejection from U.S. drug regulators.
Sanofi: Sanofi's Wayrilz approved in Japan to treat immune thrombocytopenia
Sanofi's Wayrilz approved in Japan to treat immune thrombocytopenia Wayrilz is a BTK inhibitor that works through multi-immune modulation to help address the underlying causes of immune thrombocyto...
Press Release: Sanofi's Wayrilz approved in Japan to treat immune thrombocytopenia
Sanofi's Wayrilz approved in Japan to treat immune thrombocytopenia Wayrilz is a BTK inhibitor that works through multi-immune modulation to help address the underlying causes of immune thrombocytopen...
Sanofi: Sanofi's Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses
Sanofi's Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses Cenrifki represents a significant advanc...
The Department of Health - Abu Dhabi: DoH and Sanofi Partner to Advance Vaccine Innovation
ABU DHABI, UAE, June 23, 2026 /PRNewswire/ -- The Department of Health - Abu Dhabi (DoH), the regulator of the healthcare sector in Abu Dhabi, and Sanofi, a worldwide biopharma and vaccines leader...
Sanofi (SNY) Drives $24.5M Milestone Payment to MacroGenics
Sanofi (SNY) Drives $24.5M Milestone Payment to MacroGenics
MacroGenics, Inc.: MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD Approval
ROCKVILLE, MD, June 22, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the t...
MacroGenics to receive $24.5M milestone payment from Sanofi
MacroGenics (MGNX) announced that it will receive a $24.5M regulatory milestone payment from Sanofi (SNY) following the U.S. Food and Drug Administration’s accelerated approval of TZIELD to delay the ...
MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD Approval
ROCKVILLE, MD, June 22, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treat...
Sanofi (SNY) Appoints New R&D Chief Amidst Mixed Expectations
Sanofi (SNY) Appoints New R&D Chief Amidst Mixed Expectations
Sanofi appoints Paulo Fontoura as Global Head of R&D
Sanofi (SNY) announced the appointment of Paulo Fontoura, MD, PhD, FAAN, as Executive Vice President, Global Head of Research & Development Pharma, effective September 1. “He will be a member…
Sanofi investors likely to view new R&D head as a positive, says BofA
After Sanofi (SNY) announced a new head of R&D with Paulo Fontoura replacing Houman Ashrafian, BofA analyst Sachin Jain says investors are likely to view Fontoura’s appointment as a positive…
Japan's MHLW Approves Sanofi's Subcutaneous Sarclisa For Multiple Myeloma
(RTTNews) - Sanofi (SNY) announced that the Ministry of Health, Labour, and Welfare, or MHLW, in Japan, has granted clearance for the Sarclisa subcutaneous (SC) formulation in combination with approve...
Sanofi: Sanofi appoints Paulo Fontoura as Global Head of R&D
Sanofi appoints Paulo Fontoura as Global Head of R&D Paris, June 22, 2026. Sanofi today announced the appointment of Paulo Fontoura, MD, PhD, FAAN, as Executive Vice President, Global Head of Resea...
Press Release: Sanofi appoints Paulo Fontoura as Global Head of R&D
Sanofi a ppoints Paulo Fontoura as Global Head of R&D Paris , June 22 , 2026. Sanofi today announced the appointment of Paulo F o ntoura , MD, PhD, FAAN, as Executi v e Vice President, G...